Besremi (ropeginterferon alfa-2b-njft) — United Healthcare

Initial criteria

• Diagnosis of polycythemia vera OR
• Drug recognized for treatment of the cancer indication by the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B

Approval duration

12 months